-
1.发明授权公开(公告)号：US11648225B2
公开(公告)日：2023-05-16
申请号：US17886926
申请日：2022-08-12
IPC分类号： A61K31/198 , A61K47/40 , C07D319/18 , C07D217/02 , C07D213/65 , C07D235/06 , A61K31/357 , A61K31/472 , A61K31/44 , A61K31/4184 , A61P25/28 , A61P37/06 , A61K9/00 , A61K9/08 , C07C235/34
CPC分类号： A61K31/198 , A61K9/0053 , A61K9/08 , A61K31/357 , A61K31/4184 , A61K31/44 , A61K31/472 , A61K47/40 , A61P25/28 , A61P37/06 , C07C235/34 , C07D213/65 , C07D217/02 , C07D235/06 , C07D319/18
摘要： Provided herein are compounds and their pharmaceutically acceptable salts, lipid particles comprising such compounds or pharmaceutically acceptable salts thereof and compositions of the foregoing that can be used to reduce immune intolerance in a subject, for example, to treat autoimmune disorders, or in combination with an antigenic therapy, such as a protein or gene therapy, to improve the efficacy of the antigenic therapy. The compounds have the following structural formula:
wherein values for the variables (e.g., Ring A, L, R1, R2, R3, m) are as described herein.-
2.发明授权公开(公告)号：US12016836B2
公开(公告)日：2024-06-25
申请号：US18168128
申请日：2023-02-13
IPC分类号： A61K31/198 , A61K9/00 , A61K9/08 , A61K31/357 , A61K31/4184 , A61K31/44 , A61K31/472 , A61K47/40 , A61P25/28 , A61P37/06 , C07C235/34 , C07D213/65 , C07D217/02 , C07D235/06 , C07D319/18
CPC分类号： A61K31/198 , A61K9/0053 , A61K9/08 , A61K31/357 , A61K31/4184 , A61K31/44 , A61K31/472 , A61K47/40 , A61P25/28 , A61P37/06 , C07C235/34 , C07D213/65 , C07D217/02 , C07D235/06 , C07D319/18
摘要： Provided herein are compounds and their pharmaceutically acceptable salts, lipid particles comprising such compounds or pharmaceutically acceptable salts thereof and compositions of the foregoing that can be used to reduce immune intolerance in a subject, for example, to treat autoimmune disorders, or in combination with an antigenic therapy, such as a protein or gene therapy, to improve the efficacy of the antigenic therapy. The compounds have the following structural formula:
wherein values for the variables (e.g., Ring A, L, R1, R2, R3, m) are as described herein.-
公开(公告)号：US20240173389A1
公开(公告)日：2024-05-30
申请号：US18279612
申请日：2022-03-11
发明人： Anas Fathallah , Abdulraouf Ramadan
IPC分类号： A61K39/00 , A61K9/00 , A61K9/127 , A61K31/198 , A61K31/661 , A61K45/06 , A61P37/06
CPC分类号： A61K39/0008 , A61K9/0019 , A61K9/127 , A61K31/198 , A61K31/661 , A61K45/06 , A61P37/06 , A61K2039/55555
摘要： Provided herein are compositions comprising amino acids, e.g., hydroxyamino acids, thioamino acids, or pharmaceutically acceptable salts thereof, that can be used to reduce immune intolerance in a subject. The compositions can be used, for example, to treat autoimmune disorders or in combination with an antigenic therapy, such as a protein or gene therapy, to improve the efficacy of the antigenic therapy.
-
4.发明公开公开(公告)号：US20240351977A1
公开(公告)日：2024-10-24
申请号：US18579943
申请日：2022-08-12
IPC分类号： C07C237/12 , A61K9/127 , A61K39/00 , A61K39/39 , C07C271/22 , C12N15/86
CPC分类号： C07C237/12 , A61K9/127 , A61K39/39 , C07C271/22 , C12N15/86 , A61K2039/542 , A61K2039/55555 , C12N2750/14143
摘要： Provided herein are compounds and their pharmaceutically acceptable salts, lipid particles comprising such compounds or pharmaceutically acceptable salts thereof and compositions of the foregoing that can be used to reduce immune intolerance in a subject, for example, to treat autoimmune disorders, or in combination with an antigenic therapy, such as a protein or gene therapy, to improve the efficacy of the antigenic therapy. The compounds have the following structural formula: wherein values for the variables (e.g., X, R) are as described herein.
-
5.发明申请公开(公告)号：US20230089267A1
公开(公告)日：2023-03-23
申请号：US17886926
申请日：2022-08-12
IPC分类号： A61K31/198 , C07C235/34 , C07D319/18 , C07D217/02 , C07D213/65 , C07D235/06 , A61K31/357 , A61K31/472 , A61K31/44 , A61K31/4184 , A61P25/28 , A61P37/06 , A61K9/00 , A61K9/08 , A61K47/40
摘要： Provided herein are compounds and their pharmaceutically acceptable salts, lipid particles comprising such compounds or pharmaceutically acceptable salts thereof and compositions of the foregoing that can be used to reduce immune intolerance in a subject, for example, to treat autoimmune disorders, or in combination with an antigenic therapy, such as a protein or gene therapy, to improve the efficacy of the antigenic therapy. The compounds have the following structural formula: wherein values for the variables (e.g., Ring A, L, R1, R2, R3, m) are as described herein.
-
6.发明公开公开(公告)号：US20240299327A1
公开(公告)日：2024-09-12
申请号：US18659715
申请日：2024-05-09
IPC分类号： A61K31/198 , A61K9/00 , A61K9/08 , A61K31/357 , A61K31/4184 , A61K31/44 , A61K31/472 , A61K47/40 , A61P25/28 , A61P37/06 , C07C235/34 , C07D213/65 , C07D217/02 , C07D235/06 , C07D319/18
CPC分类号： A61K31/198 , A61K9/0053 , A61K9/08 , A61K31/357 , A61K31/4184 , A61K31/44 , A61K31/472 , A61K47/40 , A61P25/28 , A61P37/06 , C07C235/34 , C07D213/65 , C07D217/02 , C07D235/06 , C07D319/18
摘要： Provided herein are compounds and their pharmaceutically acceptable salts, lipid particles comprising such compounds or pharmaceutically acceptable salts thereof and compositions of the foregoing that can be used to reduce immune intolerance in a subject, for example, to treat autoimmune disorders, or in combination with an antigenic therapy, such as a protein or gene therapy, to improve the efficacy of the antigenic therapy. The compounds have the following structural formula:
wherein values for the variables (e.g., Ring A, L, R1, R2, R3, m) are as described herein.-
7.发明公开公开(公告)号：US20230263760A1
公开(公告)日：2023-08-24
申请号：US18168128
申请日：2023-02-13
IPC分类号： A61K31/198 , C07D217/02 , A61K47/40 , C07D213/65 , A61K31/357 , C07D235/06 , A61K9/08 , A61P37/06 , A61K9/00 , C07C235/34 , C07D319/18 , A61K31/4184 , A61K31/44 , A61K31/472 , A61P25/28
CPC分类号： A61K31/198 , C07D217/02 , A61K47/40 , C07D213/65 , A61K31/357 , C07D235/06 , A61K9/08 , A61P37/06 , A61K9/0053 , C07C235/34 , C07D319/18 , A61K31/4184 , A61K31/44 , A61K31/472 , A61P25/28
摘要： Provided herein are compounds and their pharmaceutically acceptable salts, lipid particles comprising such compounds or pharmaceutically acceptable salts thereof and compositions of the foregoing that can be used to reduce immune intolerance in a subject, for example, to treat autoimmune disorders, or in combination with an antigenic therapy, such as a protein or gene therapy, to improve the efficacy of the antigenic therapy. The compounds have the following structural formula:
wherein values for the variables (e.g., Ring A, L, R1, R2, R3, m) are as described herein.
-
-
-
-
-
-
搜索结果
7 条记录 (耗时 0.01 秒)
